ReviewClinical journal of gastroenterology2014
Diagnosis and management of intestinal Behçet's disease.
Review in Clinical journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Trial
- Intestinal Behçet's disease presenting with intestinal obstruction misdiagnosed as Crohn's disease: a case report.Journal of medical case reports · 2025Article
- Myelodysplastic Syndrome With Trisomy 8 and Behçet Disease-Like Intestinal and Upper Gastrointestinal Involvement.Clinical case reports · 2025Article
- [Pathogenesis and treatment progression of myelodysplastic syndrome combined with BehçetZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet's Disease: A Post-Marketing Surveillance.Advances in therapy · 2024Observational
- Beyond the Usual Suspects: Unraveling the Etiology of Abdominal Pain with Behcet's Disease Intestinal Manifestation.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.BMC gastroenterology · 2023Observational
- Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.The Korean journal of internal medicine · 2023Article
- The treatment principles and targets for intestinal Behcet's disease.Therapeutic advances in gastroenterology · 2023Review
- Human neutrophil peptides 1-3 protect the murine urinary tract from uropathogenicProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Bilateral pneumothorax and pneumomediastinum during colonoscopy in a patient with intestinal Behcet's disease: A case report.World journal of clinical cases · 2022Article
- Behcet's disease manifesting as esophageal variceal bleeding: A case report.World journal of clinical cases · 2021Article
- Somatic symptoms with psychogenic or psychiatric background: Characteristics and pitfalls.Journal of family medicine and primary care · 2021Article
- Case Report: A Case of Intestinal Behçet's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab.Frontiers in medicine · 2021Article
- Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.Journal of gastroenterology · 2020Article
- Geographical variations in ocular and extra-ocular manifestations in Behçet's disease.European journal of rheumatology · 2019Article
- Behçet's Disease: An Overview of Etiopathogenesis.Frontiers in immunology · 2019Review
- Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.Gut and liver · 2018Review
- A case of Behçet's disease with various gastrointestinal findings.Clinical journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.